Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRI vs NALIRINOX in Metastatic PDAC (NALPAC)
NCT05472259Phase 2Recruiting
- Sponsor
- Belgian Group of Digestive Oncology
- Start
- May 2022
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Belgian Group of Digestive Oncology. Started May 2022; status: recruiting.
02
Drugs
oxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05472259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472259.